Skip to main content

Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients



Linear IgA bullous dermatosis (LABD) is a rare autoimmune subepithelial vesiculobullous disease due to IgA autoantibodies directed against different antigens of the basement membrane zone (BMZ) of the skin and/or mucosae. It affects mainly preschool-aged children and adults, with only few studies on large series. The aim of this study was to assess possible differences between adults and children regarding clinical presentation, immunopathologic features, management and course of the disease.


A retrospective review of 38 LABD patients, followed-up from November 2006 to September 2018, was performed.


Of 38 patients, 27 were adults and 11 children. Mean age at diagnosis was 5.4 years and 60.6 years in the pediatric and adult group, respectively. Considering both groups, limbs were the most commonly involved site (73.7%), followed by trunk (55.3%), head (36.8%) and buttocks (13.2%). Interestingly, head (p = 0.008), particularly perioral (p = 0.001), involvement, as well as “string of pearls” arrangement (p = 0.03), were more prevalent in children. Mucosal involvement was seen in 9 (23.7%) patients and was more frequent in children than adults (45.5% vs 14.8%, respectively, p = 0.09). Linear IgA deposits along the BMZ were observed in 30 patients (78.9%), while linear/granular IgA deposits in 8 patients (21.1%). Dapsone was the most commonly used drug (78.9%) and complete remission was achieved in most cases (81.6%).


Our epidemiological and clinicopathological findings relative to a large cohort of LABD patients are mostly consistent with the literature data. Interestingly, head, notably perioral, involvement and “string of pearls” arrangement occurred more frequently in the paediatric than adult group. The above clinical parameters may be regarded as diagnostic tools for LABD in children.


Linear immunoglobulin A (IgA) bullous dermatosis (LABD, ORPHA: 46488) is a rare autoimmune subepithelial vesiculobullous disease caused by IgA autoantibodies directed against different antigens of the basement membrane zone (BMZ) of the skin and/or mucosae [1, 2]. On direct immunofluorescence (DIF), LABD is characterized by linear deposition of IgA along the BMZ, with the possible presence of circulating IgA anti-BMZ antibodies [3]. Both children and adults may be affected, with a bimodal age of onset. In children, LABD typically manifests as tense arciform blisters that may show a “string of pearls” configuration and an erythematous/urticarial base. The preferential sites are reported to be the anogenital area and lower abdomen in children, whilst the trunk and extensor surface of the limbs in adults [1]. The childhood variant, formerly known as chronic bullous disease of the childhood (CBDC), has usually a self-healing course, albeit in few cases it may persist until adulthood [4,5,6,7,8,9,10]. Although in the past the adult- and childhood-onset variants were considered as distinct diseases, currently it is widely recognized that these two conditions share the same etiopathogenetic mechanisms and, consequently, have to be unified into a single entity [1]. LABD is a rare disease with an incidence ranging from 0.1 new cases per million population in Germany [11] to 1.45 new cases per million population in Uganda [12]. Mucous membrane involvement, notably oral cavity and conjunctiva, is relatively frequent, potentially leading to scarring sequelae [3, 13,14,15,16]. LABD may be idiopathic or due to different triggering factors, including drugs [15,16,17]. The mainstay of therapy consists of dapsone. In refractory cases, sulfapyridine may be combined or, alternatively, other therapeutic strategies, such as systemic corticosteroids, cyclosporine, colchicine, erythromycin, and intravenous immunoglobulins, may be used [1].

Literature is lacking retrospective studies on LABD from Italy, as only a few case reports have been published [18,19,20,21,22,23,24,25,26,27,28,29]. Therefore, to expand the knowledge about epidemiological aspects, clinicopathological features, course and management of LABD, we retrospectively studied patients followed-up at a single tertiary care center in Milan (Northern Italy) in order to assess the possible differences between adults and children.

Materials and methods

Patients and methods

We retrospectively examined medical records of LABD patients admitted to our outpatient service from November 2006 to September 2018. The diagnosis of LABD was rendered based on both clinical examination and immunopathological criteria [2, 30]. Inclusion criteria were: (i) presence of cutaneous manifestations consisting of tense blisters and/or vesiculobullous lesions and/or erosions, which might show a “string of pearls” configuration, and/or urticaria-like or prurigo-like lesions, possibly associated with oral, conjunctival, nasal or genital mucous membrane involvements consisting of blisters and/or erosions (ii) DIF of perilesional skin showing linear or linear/granular IgA deposition along the BMZ (when concomitant complement fraction 3 [C3c], IgG and/or IgM deposits along the BMZ were observed on DIF, the diagnosis of LABD was confirmed only if IgA deposits were predominant). Indirect immunofluorescence (IIF) with salt-split skin was performed to detect IgA and IgG deposits only in selected cases when the diagnosis was uncertain. Patients with predominant/exclusive mucosal manifestations were diagnosed as having mucous membrane pemphigoid (MMP) based on the diagnostic criteria set up in the first international consensus on MMP [31]; therefore, they were excluded from the study. In all patients with linear/granular IgA deposits on DIF, a possible diagnosis of dermatitis herpetiformis (DH) was ruled out on the basis of the negativity of serum IgA antibodies against both tissue transglutaminase and endomysium. Clinical parameters collected included sex, age at disease onset, comorbidities, pre-biopsy differential diagnosis, involved sites and clinical presentation, management strategies, and outcome at the last follow-up. Drug-induction was assessed by means of Naranjo score (NS), with an at least probable score (> 4) as the threshold to diagnose drug-induced LABD [32]. “Complete remission” (CR) was defined as the absence of new and/or established lesions for at least 2 months without or with minimal therapy. “Minimal therapy” was considered as less than or equal to 0.2 mg/kg/day of dapsone and/or 0.1 mg/kg/day of prednisone (or the equivalent) and/or minimal adjuvant or maintenance therapy. “Partial remission” (PR) was defined as the presence of transient (healing within a week) new lesions without or with minimal therapy, as defined above. No response (NR) was defined as the presence of persistent (not healing within a week) new lesions despite therapy (Additional file 1: Table S1). Relapses were defined as the reappearance of LABD manifestations in patients who showed an at least 4-month duration CR.

Statistical analysis

Categorical variables are reported as number (percentage), and continuous variables as mean (range). Data analysis was performed with Fisher’s exact test, as appropriate, using GraphPad Prism version 6.0 (GraphPad Software, Inc., San Diego, CA). Statistical significance was defined as p ≤ 0.05.


Patients and clinical findings

Detailed clinical and laboratory data of the 38 collected patients are shown in Additional file 1: Table S1 included in the manuscript as additional file. They had an average age at diagnosis of 45.7 years (range 0.9–93 years). In the 11 patients (28.9%) diagnosed before 16 years old, the mean age at diagnosis was 5.4 years, while in the adult group it was 60.6 years. The overall male to female ratio was 1.2. It was lower in adults (0.9) than in children (2.7), even though, as shown in Table 1, there were no statistically significant differences in sex preponderance between adults and children. Concerning comorbidities, four patients had a history of neoplasm, two were affected by ulcerative colitis and one by coeliac disease. This last patient displayed linear/granular IgA deposits, making it mandatory to rule out DH. Thus, we performed salt-split skin IIF that showed linear IgA deposits along the epidermal side of the BMZ, consistent with LABD. At the time of diagnosis, bullous and/or vesiculobullous elements on erythematous (Fig. 1b and d) or non-inflamed skin represented the most commonly observed (n = 35; 92.1%) skin lesions. The “string of pearls” arrangement (Fig. 1a and c) was described in 8 patients (21.1%) and resulted significantly more frequent in children than in adults (45.5% vs 11.1%; p = 0.03), as shown in Table 1. In a single case, only urticaria-like lesions were present, while in two cases crusts, erosions and excoriated lesions were the only cutaneous findings. Skin lesions were located on the limbs (n = 28: 73.7%), trunk (n = 21; 55.3%), head (n = 14; 36.8%) and buttocks (n = 5; 13.2%). Head involvement was more common in children than adults (72.7% vs 22.2%; p = 0.008) and, when considering only the perioral area, the statistical significance increased (54.5% vs 3.7%; p = 0.001). Mucous membrane involvement was observed in 9 (23.7%) patients and the most frequent mucosal localisation was oral cavity (15.8%), followed by genital (7.8%) (Fig. 1e), conjunctival (5.2%) and nasal cavity (2.6%) involvements. Mucosae were more frequently involved in children than adults (45.5% vs 14.8%, respectively; p = 0.09) and, interestingly, all patients with genital involvement (n = 3) were children. Pre-biopsy diagnostic hypothesis was correct in 7 cases (18.4%), while bullous pemphigoid (BP) (n = 10; 26.3%) and bullous impetigo (n = 5; 13.2%) represented the most frequent misdiagnoses. All but two cases were idiopathic; the two probably drug-induced cases were triggered by amoxicillin/clavulanic acid (NS = 6) and clarithromycin (NS = 5), with a latency time from the intake of 1 and 3 weeks, respectively. Losartan (NS = 2), oxcarbazepine (NS = 3) and chlorambucil (NS = 2) were regarded as possible culprit drugs in three other cases.

Table 1 Clinical and laboratory characteristic of adults and children with LABD
Fig. 1
figure 1

Linear IgA bullous dermatosis. a Widespread vesiculobullous eruption on the lower limbs with elements in a “string of pearls” arrangement; (b) targetoid vesicular lesions on erythematous skin involving the dorsa of the hands; (c) blisters with a “string of pearls” configuration and crusts in the perioral area; (d) erythematous, vesicular lesions partially eroded on the posterior aspects of both thighs; (e) vesicles involving the vulvar area in a child

Histology and immunofluorescence results

Histological examination on skin or mucous biopsies as well as DIF examination were routinely performed in all patients. On histopathological assessment, all cases revealed subepidermal blisters associated with dermal infiltrate of neutrophils. In 22 cases (57.9%), eosinophils were observed in association with neutrophils in the upper dermis, without statistically significant differences between adults and children (p = 0.47). Neutrophil microabscesses at the tip of the dermal papillae were seen in three cases (7.9%).

On DIF, linear IgA deposits along the BMZ were observed in 30 patients (78.9%), while linear/granular IgA deposits were detected in 8 patients (21.1%). As shown in Table 1, no statistically significant differences were observed between adults and children in terms of positivity for linear or linear/granular IgA deposits. Linear deposits of IgA alone - with neither Ig class other than IgA nor complement - were observed in 23 cases, while linear/granular deposits of IgA alone were observed in three cases. Among the 12 cases showing deposits of Ig other than IgA or complement in addition to IgA, 11 patients had C3c, 6 had IgM and 3 had IgG. Salt-split human skin IIF was performed in 30 patients and was positive in 19 out of 30 cases (63.3%), all showing linear IgA deposits along the epidermal side of the BMZ. All cases were negative for IgG deposits on salt-split human skin IIF. Children had a higher, albeit not statistically significant, positivity rate of salt-split human skin IIF compared to adults (85.7% vs 43.5%; p = 0.21).

Treatment and follow-up

All patients except two self-resolving cases received systemic therapy, combined with topical treatment in some cases. Dapsone, administered to 30 patients (78.9%), with a mean starting dosage of 0.5 mg/kg per day, was the most common treatment option. Median duration of dapsone treatment was 26.2 months. We observed dapsone-induced methemoglobinemia only in a patient, who was switched to oral methylprednisolone and consequently showed a CR. Systemic corticosteroids (prednisone, oral and intravenous methylprednisolone, and deflazacort) were given in concomitance with, preceding or following dapsone in 22 cases (57.9%), while in 5 cases (13.2%) they represented a stand-alone therapy. In a case resistant to corticosteroid monotherapy, a combination of methotrexate and oral methylprednisolone induced a CR. Other treatment options for steroid-refractory cases are reported in Additional file 1: Table S1. Topical steroids were given to 6 patients, with clobetasol propionate being the most commonly used agent (n = 4; 10.5%). Cyclosporine eye drops were administered in two patients with ocular involvement. One adult patient with a drug-induced form and one pediatric patient received neither systemic nor topical treatments owing to a self-limiting course, with a follow-up time of 16 months in both cases. The mean follow-up time was 30.7 months. CR was achieved in most cases (n = 31; 81.6%), while PR in three patients. Only two cases were refractory to multiple drugs, showing NR (Additional file 1: Table S1). Scarring sequelae were observed in two cases showing aggressive conjunctival involvement. Relapses were observed in five patients (adults, n = 4; children, n = 1), with no statistically significant differences between adults and children. All patients with relapsed disease were not taking any medication for their LABD at the moment of the relapse. The mean time from drug withdrawal to relapse was 10 months. All patients who experienced a relapse re-achieved a CR after treatment reintroduction. As shown in Table 1, no statistically significant differences were found between the adult and pediatric group in terms of response to treatment.


We present the largest case-series of Italian patients with LABD and compare our findings with data reported in the literature (Additional file 2: Table S2). Our results confirmed the bimodal age at onset of this disease [1], with two different groups represented by children and adults. Although an overall similar prevalence in males and females was outlined, stratifying the population in terms of age, our data revealed a preponderance of the disease, albeit not statistically significant, in male children, as already observed by other authors [7,8,9].

Regarding clinical manifestations, of note, in our study head, particularly perioral, involvements were significantly more common in the pediatric than adult group (72.7% vs 22.2%; p = 0.008 and 54.5% vs 3.7%; p = 0.001, respectively). This is in line with literature data reporting the head and face more commonly involved in children than adults [6]. Furthermore, the “string of pearls” arrangement was significantly more frequent in children than adults (p = 0.03), similarly to the findings of Jabłońska et al. [5], with an overall prevalence of 21%. Consistent with data reporting high prevalences of genital involvement in the pediatric population [5], all patients with genital involvement were children.

Gottlieb et al. [14] showed that 60% of a case series of 72 adults with LABD had mucous membrane involvement, suggesting that the term “linear IgA disease” might be more suitable than “linear IgA dermatosis”. On the other hand, data about mucous membrane involvement in children are controversial, since a study by Wojnarowska et al. [6] disclosed a prevalence of mucosal involvement of 64% in 25 LABD children, but more recent case series revealed lower prevalences [9, 10, 33]. In our study, mucosal involvement resulted less common than that reported by Wojnarowska et al. [6] and it was more frequent in children than adults (45.5% vs 14.8%, respectively), albeit without statistically significant difference.

We regarded drugs as a probable or possible cause of LABD in 13.2% of our cohort, a lower prevalence as compared to the study of Lings et al., which identified possibly/probably drug-induced LABD in 6 out of 23 (26.1%) cases [34]. Although both Chanal et al. [16] and Garel et al. [15] concluded in two independent retrospective studies that drug-induced LABD might be more severe and mimic toxic epidermal necrolysis (TEN), both our drug-induced cases lacked TEN-like features and achieved a CR upon treatment.

The increasingly described association of LABD with inflammatory bowel diseases [35,36,37] was confirmed by our study, showing an ulcerative colitis prevalence of 5.6%, much higher than 0.12% estimated in the Italian general population [38]. Immune activation secondary to the exposition of multiple intestinal epithelial antigens, included BP180, in patients with coexistence of LABD and inflammatory bowel diseases has been hypothesized as a possible pathomechanism eliciting blister formation [35].

Approximately 15% of the adult patients had a history of cancer. Although malignancies, especially of lymphoreticular origin, have been described in association with LABD, [39] in all our cases the lack of a close temporal relationship between the onset of LABD and the underlying neoplasm made it unlikely the hypothesis of a paraneoplastic disease.

Linear IgA deposition along the BMZ with neither Ig class other than IgA nor complement resulted the most frequent pattern on DIF in our case series. In our study, patients with linear IgG deposits in addition to linear IgA deposits were considered as a subgroup of LABD. Indeed, Ohata et al. [3] suggested linear IgA/IgG bullous dermatosis as part of a spectrum of diseases ranging from LABD to BP.

IIF on human skin has been reported to be positive for IgA in just over 80% of children and approximately 40% of adults [40] and salt-split skin technique demonstrated an increase in the sensitivity of IIF [3, 14, 40]. In our study, salt-split skin IIF resulted positive in approximately 60% of patients and, in line with the results of Willsteed et al. [40], a higher, albeit not statistically significant, rate of positivity of salt-split skin IIF was observed in children as compared to adults (85.7% vs 43.5%, respectively). Moreover, all our cases showed an epidermal binding. Although IgA deposits on salt-split skin are predominantly detected on the epidermal side [40], dermal binding has been reported in 8% [3] and 17% [41] of large case series. In the study by Ohata et al. [3], binding of IgA autoantibodies to both sides of the split was observed only in 7% of patients.

Most frequent and successful treatment was dapsone, given both as a stand-alone therapy and combined with systemic steroids. In our comparison of the adult and children group, we failed to identify any differences in terms of response to treatment. As compared to the study of Gottlieb et al., [14] higher CR and lower relapse rates were observed in our patients. These differences might be due to a combination of the following aspects: (i) only adults, usually showing a more aggressive and relapsing course, have been collected in the study of Gottlieb et al.; (ii) as opposed to our study, cases with predominant mucous membrane involvement, also showing a more refractory behaviour, have been included; (iii) topical corticosteroids were the first-choice treatment in 40% of their patients, while almost all our patients received systemic treatments as first-line.

The main limitation of the present study was its retrospective nature, which, however, depended on the rarity of the disease. Furthermore, a direct comparison between the two groups might have been biased by the fact that adults were more numerous than children in the study population. An additional limitation was represented by the fact that immunoblotting and enzyme-linked immunoassay for BP180, BP230 and/or collagen VII were not performed. Therefore, it cannot be stated with certainty whether cases of sublamina densa-type LABD and IgA-epidermolysis bullosa acquisita, whose common autoantigen is collagen VII, [42,43,44] have been missed. Furthermore, establishing an accurate diagnosis of LABD may be difficult owing to the absence of unanimous consensus on diagnostic criteria. [45] In this regard, we ruled out from our study patients with linear or linear/granular IgA deposits on DIF and predominant/exclusive mucosal involvement, who, based on the first consensus conference on MMP, were classified as having IgA-MMP. [31, 46] Although our criteria may have been strict and are not fully in line with those adopted in other large series on LABD [3, 14], we believe that they are clear and have minimal risk of including MMP patients.


In summary, the results of this retrospective study conducted on a cohort of 38 Italian LABD patients diagnosed and followed-up in a single center confirmed the biphasic age at onset of the disease and showed a higher prevalence of head, particularly perioral, and mucosal involvements as well as a more frequent “string of pearls” arrangement in children than adults. Thus, these clinical parameters may be a diagnostic tool for LABD in children.



basement membrane zone


bullous pemphigoid


complement fraction 3


chronic bullous disease of the childhood


complete remission


dermatitis herpetiformis


direct immunofluorescence




indirect immunofluorescence


linear bullous IgA dermatosis


mucous membrane pemphigoid


no response


Naranjo score


partial remission


toxic epidermal necrolysis


  1. Fortuna G, Marinkovich MP. Linear immunoglobulin a bullous dermatosis. Clin Dermatol. 2012;30:38–50.

    Article  Google Scholar 

  2. Egan CA, Zone JJ. Linear IgA bullous dermatosis. Int J Dermatol. 1999;38:818–27.

    Article  CAS  Google Scholar 

  3. Ohata C, Ishii N, Koga H, Nakama T. A clinical and serological study of linear IgA bullous dermatosis without linear immunoglobulin deposition other than IgA at the basement membrane zone using direct immunofluorescence. Br J Dermatol. 2017;177:152–7.

    Article  CAS  Google Scholar 

  4. Kong YL, Lim YL, Chandran NS. Retrospective study on autoimmune blistering disease in Paediatric patients. Pediatr Dermatol. 2015;32:845–52.

    Article  Google Scholar 

  5. Jabłońska S, Chorzelski TP, Rosinska D, Maciejowska E. Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood). Clin Dermatol. 1991;9:393–401.

    Article  Google Scholar 

  6. Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol. 1988;19:792–805.

    Article  CAS  Google Scholar 

  7. Kanwar AJ, Sandhu K, Handa S. Chronic bullous dermatosis of childhood in North India. Pediatr Dermatol. 2004;21:610–2.

    Article  CAS  Google Scholar 

  8. Nanda A, Dvorak R, Al-Sabah H, Alsaleh QA. Linear IgA bullous disease of childhood: an experience from Kuwait. Pediatr Dermatol. 2006;23:443–7.

    Article  Google Scholar 

  9. Kharfi M, Khaled A, Karaa A, Zaraa I, Fazaa B, Kamoun MR. Linear IgA bullous dermatosis: the more frequent bullous dermatosis of children. Dermatol Online J. 2010;16(2).

  10. Kenani N, Mebazaa A, Denguezli M, Ghariani N, Sriha B, Belajouza C, Nouira R. Childhood linear IgA bullous dermatosis in Tunisia. Pediatr Dermatol. 2009;26:28–33.

    Article  Google Scholar 

  11. Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434–40.

    PubMed  Google Scholar 

  12. Mulyowa GK, Jaeger G, Kabakyenga J, Bröcker EB, Zillikens D, Schmidt E. Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Int J Dermatol. 2006;45:1047–52.

    Article  Google Scholar 

  13. Kelly SE, Frith PA, Millard PR, Wojnarowska F, Black MM. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol. 1988;119:161–70.

    Article  CAS  Google Scholar 

  14. Gottlieb J, Ingen-Housz-Oro S, Alexandre M, et al. Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. Br J Dermatol. 2017;177:212–22.

    Article  CAS  Google Scholar 

  15. Garel B, Ingen-Housz-Oro S, Afriat D, et al. Drug-induced linear IgA bullous dermatosis: a French retrospective pharmacovigilance study of 69 cases. Br J Clin Pharmacol. 2019;85:570–9.

    Article  CAS  Google Scholar 

  16. Chanal J, Ingen-Housz-Oro S, Ortonne N, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013;169:1041–8.

    Article  CAS  Google Scholar 

  17. Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immunoglobulin a bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol. 2012;66:988–94.

    Article  Google Scholar 

  18. Fuligni A, Di Blasi A, Borgogni L, Pimpinelli N, Moretti S, Fabbri P. A peculiar case of linear IgA bullous dermatosis. Arch Dermatol. 1991;127:126–7.

    Article  CAS  Google Scholar 

  19. Zambruno G, Manca V, Kanitakis J, Cozzani E, Nicolas JF, Giannetti A. Linear IgA bullous dermatosis with autoantibodies to a 290 kd antigen of anchoring fibrils. J Am Acad Dermatol. 1994;31:884–8.

    Article  CAS  Google Scholar 

  20. Zambruno G, Kanitakis J. Linear IgA dermatosis with IgA antibodies to type VII collagen. Br J Dermatol. 1996;135:1004–5.

    Article  CAS  Google Scholar 

  21. Pellicano R, Lomuto M, Cozzani E, Iannantuono M, De Simone C. Linear IgA bullous dermatosis after contact with sodium hypochlorite. Dermatology. 1997;194:284–6.

    Article  CAS  Google Scholar 

  22. De Simone C, Guerriero C, Pellicano R. Linear IgA disease and ulcerative colitis. Eur J Dermatol. 1998;8:48–50.

    PubMed  Google Scholar 

  23. Viglizzo G, Cozzani E, Nozza P, Occella C, Parodi A. A case of linear IgA disease in a child with IgA and IgG circulating antibodies directed to BPAg2. Int J Dermatol. 2007;46:1302–4.

    Article  CAS  Google Scholar 

  24. Marzano AV, Ramoni S, Spinelli D, Alessi E, Berti E. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium. J Dermatolog Treat. 2008;19:364–7.

    Article  CAS  Google Scholar 

  25. Antiga E, Bellandi S, Bianchi B, et al. A further case of subacute prurigo-like linear IgA bullous dermatosis: growing evidence of a new subset. Int J Dermatol. 2012;51:1500–1.

    Article  Google Scholar 

  26. Paloni G, Shardlow A, Maschio M, Berti I, Taddio A, Ventura A. A child with bullous skin lesions. Linear IgA dermatosis. JAMA Pediatr. 2013;167:975–6.

    Article  Google Scholar 

  27. Romani L, Diociaiuti A, D'Argenio P, et al. A case of neonatal linear IgA bullous dermatosis with severe eye involvement. Acta Derm Venereol. 2015;95:1015–7.

    Article  CAS  Google Scholar 

  28. Diociaiuti A, Zambruno G, Diomedi Camassei F, et al. IgA tracheobronchial deposits underlie respiratory compromise in neonatal linear IgA bullous dermatosis. J Eur Acad Dermatol Venereol. 2017;31:e333–5.

    Article  CAS  Google Scholar 

  29. Gatto A, Guerriero C, Moretta G, et al. Linear IgA bullous dermatosis in a two-year-old child: possible association with aspirin. Eur J Dermatol. 2017;27:417–8.

    PubMed  Google Scholar 

  30. Leonard JN, Haffenden GP, Ring NP, et al. Linear IgA disease in adults. Br J Dermatol. 1982;107:301–16.

    Article  CAS  Google Scholar 

  31. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–9.

    Google Scholar 

  32. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.

    Article  CAS  Google Scholar 

  33. Horiguchi Y, Ikoma A, Sakai R, Masatsugu A, Ohta M, Hashimoto T. Linear IgA dermatosis: report of an infantile case and analysis of 213 cases in Japan. J Dermatol. 2008;35:737–43.

    Article  CAS  Google Scholar 

  34. Lings K, Bygum A. Linear IgA bullous dermatosis: a retrospective study of 23 patients in Denmark. Acta Derm Venereol. 2015;95:466–71.

    Article  Google Scholar 

  35. Shipman AR, Reddy H, Wojnarowska F. Association between the subepidermal autoimmune blistering diseases linear IgA disease and the pemphigoid group and inflammatory bowel disease: two case reports and literature review. Clin Exp Dermatol. 2012;37:461–8.

    Article  CAS  Google Scholar 

  36. Walker SL, Banerjee P, Harland CC, Black MM. Remission of linear IgA disease associated with ulcerative colitis following panproctocolectomy. Br J Dermatol. 2000;143:1341–2.

    Article  CAS  Google Scholar 

  37. Paige DG, Leonard JN, Wojnarowska F, Fry L. Linear IgA disease and ulcerative colitis. Br J Dermatol. 1997;136:779–82.

    Article  CAS  Google Scholar 

  38. Trallori G, Palli D, Saieva C, et al. A population-based study of inflammatory bowel disease in Florence over 15 years (1978–92). Scand J Gastroenterol. 1996;31:892–9.

    Article  CAS  Google Scholar 

  39. Kartan S, Shi VY, Clark AK, Chan LS. Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment. Am J Clin Dermatol. 2017;18:105–26.

    Article  Google Scholar 

  40. Willsteed E, Bhogal BS, Black MM, McKee P, Wojnarowska F. Use of 1M NaCl split skin in the indirect immunofluorescence of the linear IgA bullous dermatoses. J Cutan Pathol. 1990;17:144–8.

    Article  CAS  Google Scholar 

  41. Lally A, Chamberlain A, Allen J, Dean D, Wojnarowska F. Dermal-binding linear IgA disease: an uncommon subset of a rare immunobullous disease. Clin Exp Dermatol. 2007;32:493–8.

    Article  CAS  Google Scholar 

  42. Tsuchisaka A, Ohara K, Ishii N, et al. Type VII collagen is the major autoantigen for sublamina densa-type linear IgA bullous dermatosis. J Invest Dermatol. 2015;135:626–9.

    Article  CAS  Google Scholar 

  43. Vodegel RM, de Jong MC, Pas HH, Jonkman MF. IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature. J Am Acad Dermatol. 2002;47:919–25.

    Article  Google Scholar 

  44. Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K. Epidermolysis bullosa Acquisita: the 2019 update. Front Med (Lausanne). 2019;5:362.

    Article  Google Scholar 

  45. Antiga E, Caproni M, Fabbri P. Linear immunoglobulin a bullous dermatosis: need for an agreement on diagnostic criteria. Dermatology. 2013;226:329–32.

    Article  CAS  Google Scholar 

  46. Di Zenzo G, Carrozzo M, Chan LS. Urban legend series: mucous membrane pemphigoid. Oral Dis. 2014;20:35–54.

    Article  Google Scholar 

Download references


We would like to thank the colleagues of the Pediatric Dermatology Unit of the “Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico” for their precious collaboration.


This study was funded with internal resources only.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author upon reasonable request.

Author information

Authors and Affiliations



GG, EB and AVM conceived the study and discussed the structure of the manuscript. SM, DF and LV contributed to the concept of the study and helped with data analysis. GG and AVM wrote the manuscript, analysed the patient data and designed the concept of table and figures in close exchange with EB. All authors contributed to the discussion and critically revised and edited the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Giovanni Genovese.

Ethics declarations

Ethics approval and consent to participate

This study was performed in accordance with the Declaration of Helsinki and the full protocol was approved by the Institutional Review Board of the Fondazione IRCCS Ca′ Granda Ospedale Maggiore Policlinico, Milan, Italy. All the subjects enrolled in the study gave their written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional files

Additional file 1:

Table S1. Demographic data, clinical features, diagnostic findings, treatments and outcomes of 38 linear IgA bullous dermatosis patients. (DOCX 37 kb)

Additional file 2:

Table S2. Summary of the main studies on linear IgA bullous dermatosis including study design, patients’ number, clinical features and laboratory findings. (DOCX 25 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genovese, G., Venegoni, L., Fanoni, D. et al. Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients. Orphanet J Rare Dis 14, 115 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: